The news: A “real-world” study of 3,950 people in six states found that two doses of Pfizer/BioNTech and Moderna’s vaccines cut the risk of infection by 90%. The findings are broadly in line with the 95% and 94% efficacy that Pfizer and Moderna vaccines showed, respectively, in their clinical trials.
The details: The Centers for Disease Control and Prevention study recruited essential workers, including healthcare workers, and followed them over a 13-week period from December 2020 to March 2021, requiring them to take weekly tests. Almost 75% of the group received at least one dose of one of the mRNA vaccines. Among the cohort that received both doses, vaccine effectiveness was 90%. For the group that had received just one dose, effectiveness was 80% after two weeks. There were 161 covid-19 infections among the unvaccinated group, compared with 16 who had received one dose, and just three in people who had received both doses. There were no covid-19 deaths in the study.
Solid findings: This new study provides yet more promising data on the positive effect vaccines are starting to have on the pandemic. Last month, England’s health authority reported that a single shot of either the Oxford/AstraZeneca or the Pfizer/BioNTech vaccine cut the chance of needing hospital treatment by more than 80%. Israel, which has vaccinated more than half its population, recently reported that the Pfizer/BioNTech vaccine had 94% efficacy against infection and 92% against severe disease.
A worrying catch: Cases are on the rise again in several US states, despite the rapidly accelerating vaccine program (72% of Americans 65 and older have now been vaccinated). The increase is most likely thanks to the effect of the more transmissible UK variant. The growing spread of variants makes the need for as many as people as possible to get vaccinated even more urgent—not only in the US, but in countries around the world as supplies have already been bought up. Many countries are yet to vaccinate anyone. The more the virus is allowed to spread, the higher the chance of variants emerging—and potentially variants which can escape existing vaccines.